Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) — The “Haemophilia Treatment Market – Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F” report has been added to ResearchAndMarkets.com’s offering.
The Haemophilia Treatment Market was valued at USD 11.38 Billion in 2024, and is expected to reach USD 15.73 Billion by 2030, rising at a CAGR of 5.74%
Pharmaceutical companies have the resources and expertise to develop and manufacture novel therapies. Research institutions contribute scientific knowledge and innovation, while patient organizations provide insights into the lived experiences of individuals with hemophilia. By working together, these entities can combine their strengths to tackle complex challenges.
Collaborations enable researchers to pool their knowledge and data, expediting the research process. This can lead to quicker identification of potential drug candidates, streamlined clinical trials, and faster regulatory approvals. Patient organizations represent the voices and needs of individuals living with hemophilia. Their involvement ensures that new treatments are designed with patient preferences in mind, enhancing treatment adherence and overall satisfaction.
Collaborations can facilitate patient access to clinical trials of experimental treatments. Patient organizations often play a crucial role in connecting eligible individuals with these opportunities, ensuring that clinical trial participants are representative of the patient population.
Gene Therapy Advancements
Gene therapy for hemophilia is a promising and groundbreaking area of research that holds the potential to revolutionize the treatment landscape for individuals with hemophilia. This innovative approach aims to address the root cause of the condition by introducing functional clotting factor genes into a patient’s body. As gene therapy techniques become more refined and successful, they offer the possibility of not just managing hemophilia but potentially curing it, eliminating the lifelong need for clotting factor infusions.
Unlike traditional treatments that manage symptoms, gene therapy seeks to modify the underlying genetic defect responsible for hemophilia. By introducing functional clotting factor genes into the body, it has the potential to restore the ability to produce clotting factors naturally. Gene therapy offers the possibility of a preventive approach to hemophilia, where patients may no longer need to worry about bleeding episodes and can lead more normal, active lives.
While gene therapy for hemophilia holds immense promise, there are still challenges to overcome, including long-term safety and durability of the treatment effects, broader accessibility, and potential immune responses to the gene therapy vectors. However, ongoing research and development efforts are aimed at addressing these challenges, and the potential for a cure for hemophilia through gene therapy is an exciting prospect that offers hope to individuals and families affected by this rare bleeding disorder.
Segmental Insights
Type Insights
Based on the Type, Hemophilia A emerged as the fastest growing segment in the Global Haemophilia Treatment Market in 2024. This genetic disorder is characterized by a deficiency in blood clotting factor VIII, leading to prolonged bleeding episodes. The prevalence of hemophilia A in developed regions, coupled with supportive government initiatives, has been instrumental in driving its market dominance.
Major markets such as the U.S., Europe, and Japan have witnessed the launch of innovative products, further bolstering the market position of Hemophilia A. According to a survey conducted by the World Federation of Hemophilia (WFH) in 2020, countries like the U.S., India, and Brazil have reported a significant number of Hemophilia A cases, estimated to be around 10,000. This underscores the pressing need for effective treatment and management strategies to address this complex genetic disorder.
Treatment Insights
Based on the Treatment, On-demand emerged as the dominant segment in the Global Haemophilia Treatment Market in 2024. This is reflecting its critical role in managing acute bleeding episodes and its widespread adoption among patients. On-demand treatment involves administering clotting factor replacement therapies or other hemostatic agents immediately after the onset of a bleeding event, ensuring rapid control and minimizing potential complications.
One of the key drivers for the dominance of the on-demand segment is its practicality and cost-effectiveness, especially for patients with mild to moderate hemophilia who may not require routine prophylaxis. It provides targeted intervention, reducing the risk of unnecessary treatment and associated expenses. Moreover, advancements in recombinant therapies and extended half-life clotting factors have enhanced the efficacy and convenience of on-demand treatments, making them more appealing to both healthcare providers and patients.
Regional Insights
North America emerged as the dominant region in the global hemophilia treatment market in 2024. This is driven by a combination of advanced healthcare infrastructure, high disease awareness, and robust investment in research and development. The region’s leadership is primarily attributed to the United States, which boasts cutting-edge medical facilities and a strong focus on innovative therapies for hemophilia.
A key factor contributing to this dominance is the widespread availability of advanced treatment options, including recombinant clotting factors, extended half-life therapies, and emerging gene therapies. These treatments, coupled with favorable reimbursement policies, have significantly enhanced access for patients, leading to improved disease management outcomes. Moreover, the region’s healthcare systems are equipped with specialized hemophilia treatment centers (HTCs), which provide comprehensive care and promote adherence to treatment protocols.
North America also benefits from a high prevalence of hemophilia awareness campaigns and patient advocacy initiatives, which play a critical role in early diagnosis and effective disease management. The focus on innovation is further underscored by significant R&D investments from leading biopharmaceutical companies in the region, resulting in the development of novel therapeutics and personalized approaches to hemophilia care.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2024 – 2030 |
| Estimated Market Value (USD) in 2024 | $11.38 Billion |
| Forecasted Market Value (USD) by 2030 | $15.73 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
Report Scope:
Key Market Players
- Bayer AG
- BioMarin Pharmaceutical, Inc.
- CSL Behring LLC
- Kedrion S.p.A
- Novo Nordisk A/S
- Pfizer, Inc.
- Octapharma AG
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Grifols S.A.
Haemophilia Treatment Market, By Type:
- Haemophilia A
- Haemophilia B
- Haemophilia C
Haemophilia Treatment Market, By Product:
- Recombinant Coagulation Factor Concentrates
- Plasma Derived Coagulation Factor Concentrate
- Desmopressin
- Antifibrinolytics Agents
Haemophilia Treatment Market, By Treatment:
Haemophilia Treatment Market, By Therapy:
- Replacement Therapy
- ITI therapy
- Gene Therapy
Haemophilia Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
For more information about this report visit https://www.researchandmarkets.com/r/jldydf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Haemophilia Treatment Market
